FDA says its safety review of abortion pill will continue into next year

The Food and Drug Administration's timeline was quickly condemned by abortion opponents hoping to see mifepristone's use curtailed.

FDA向法院提交的最新進展顯示，對米非司酮的安全性審查要到2027年3月才有報告，之後才決定是否加限制，反墮胎團體對此表示不滿。報道同時交代了該藥的歷史審批、各州訴訟與郵寄處方爭議等背景。